Phase II, single-arm, prospective clinical study of Toripalimab(a PD-1 antibody) combined with radiotherapy and chemotherapy in the treatment of sinonasal malignant mucosal melanoma after endoscopic surgery.
Study Type
INTERVENTIONAL
Allocation
NA
Purpose
TREATMENT
Masking
NONE
Enrollment
45
endoscopic surgery followed by multimodality treatment including radiotherapy,Toripalimab,and/or chemotherapy
Eye& ENT Hospital, Fudan University
Shanghai, Shanghai Municipality, China
RECRUITINGOverall survival
3 year Overall Survival rate
Time frame: From date of first treatment until the date of death from any cause,through study completion,up to 3 years.]
progression free survival
the date of first treatment to the first recording of disease progression or death from any cause.
Time frame: From date of first treatment until the date of first documented progression or date of death from any cause, whichever came first,through study completion,up to 3 years.
This platform is for informational purposes only and does not constitute medical advice. Always consult a qualified healthcare professional.